MEMBX
Price
$30.27
Change
+$0.03 (+0.10%)
Updated
Dec 20 closing price
RNWFX
Price
$77.72
Change
+$0.12 (+0.15%)
Updated
Dec 20 closing price
Ad is loading...

MEMBX vs RNWFX

Header iconMEMBX vs RNWFX Comparison
Open Charts MEMBX vs RNWFXBanner chart's image
MFS Emerging Markets Equity B
Price$30.27
Change+$0.03 (+0.10%)
VolumeN/A
CapitalizationN/A
American Funds New World R5
Price$77.72
Change+$0.12 (+0.15%)
VolumeN/A
CapitalizationN/A
MEMBX vs RNWFX Comparison Chart
Loading...
View a ticker or compare two or three
VS
MEMBX vs. RNWFX commentary
Dec 24, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MEMBX is a StrongBuy and RNWFX is a Buy.

FUNDAMENTALS
Fundamentals
RNWFX has more cash in the bank: 62.2B vs. MEMBX (7.7B). MEMBX pays higher dividends than RNWFX: MEMBX (1.68) vs RNWFX (1.51). MEMBX was incepted earlier than RNWFX: MEMBX (29 years) vs RNWFX (23 years). MEMBX is a more actively managed with annual turnover of: 36.00 vs. RNWFX (32.00). RNWFX has a lower initial minimum investment than MEMBX: RNWFX (250) vs MEMBX (1000). MEMBX annual gain was more profitable for investors over the last year : 12.47 vs. RNWFX (5.86). RNWFX return over 5 years is better than : 14.39 vs. MEMBX (-2.28).
MEMBXRNWFXMEMBX / RNWFX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence29 years23 years-
Gain YTD10.3284.549227%
Front LoadN/AN/A-
Min. Initial Investment1000250400%
Min. Initial Investment IRA250N/A-
Net Assets7.7B62.2B12%
Annual Yield % from dividends1.681.51112%
Returns for 1 year12.475.86213%
Returns for 3 years-2.32-5.1045%
Returns for 5 years-2.2814.39-16%
Returns for 10 years24.9842.6759%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VTRS12.520.39
+3.22%
Viatris
TEO11.890.14
+1.19%
Telecom Argentina SA
DX12.570.14
+1.13%
Dynex Capital
INTT7.680.04
+0.52%
inTEST Corp
VIRX0.21N/A
-1.87%
Viracta Therapeutics